Aquestive Therapeutics Under Investigation
Investors of Aquestive Therapeutics, Inc. (NASDAQ: AQST) face unprecedented challenges due to significant losses following alarming news from the company. Leading securities law firm Faruqi & Faruqi, LLP is actively investigating these potential claims on behalf of aggrieved investors. If you have suffered notable losses, it’s crucial to understand your legal options.
The Impact of FDA Findings
Recently, shares of Aquestive Therapeutics took a sharp downturn, plummeting nearly 40% in intraday trading after the U.S. Food and Drug Administration (FDA) communicated critical deficiencies in the company's New Drug Application (NDA) for Anaphylm. This experimental sublingual film, designed for treating severe allergic reactions and anaphylaxis, has encountered serious setbacks. The FDA's identification of these deficiencies has raised doubts regarding the application's approvability, particularly with respect to its labeling and post-marketing requirements, and has placed the anticipated January 31 PDUFA action date in jeopardy.
Legal Support and Guidance
Faruqi & Faruqi, LLP, recognized for their substantial achievements in securities litigation, have secured millions for investors since its inception in 1995. Their experienced team is committed to helping investors like you navigate this trying time. If you are concerned about the impact of Aquestive's recent news on your investments, reach out directly to their Securities Litigation Partner, James (Josh) Wilson, to discuss your unique situation.
Why Investors Should Act Now
Taking swift action is crucial for investors who have incurred losses in Aquestive Therapeutics stock or options. The volatile nature surrounding the company's recent developments makes it vital to discuss legal avenues before further declines occur. Contacting a dedicated legal partner like Faruqi & Faruqi can provide necessary insights and strategies to potentially recover losses.
Investor Outreach
Faruqi & Faruqi encourages investors to contact them if they faced significant losses due to the adverse developments surrounding Aquestive Therapeutics. Investors can call 877-247-4292 or 212-983-9330 (Ext. 1310) for a direct conversation about their legal rights and options.
Updates and Information
To stay informed about the evolving situation concerning Aquestive Therapeutics, follow the updates from prominent legal experts and financial analysts. Ongoing coverage will shed light on any breakthroughs or corporate responses that may influence investor sentiment positively.
Frequently Asked Questions
What is the current status of the investigation into Aquestive Therapeutics?
Faruqi & Faruqi, LLP is currently investigating the recent FDA findings related to the firm's New Drug Application, which has impacted investor confidence.
How can I contact Faruqi & Faruqi for assistance?
Investors can reach out directly to Josh Wilson via phone at 877-247-4292 or 212-983-9330 (Ext. 1310) for personalized legal support.
What are the implications of the FDA's findings for investors?
The FDA's findings have raised concerns about the approvability of the NDA for Anaphylm, leading to significant drops in share value, which could pose a threat to investors' financial securities.
Why is it important to act quickly?
Time is of the essence for investors to protect their interests and explore potential legal avenues, as market conditions can change rapidly.
Where can I find more information on Aquestive Therapeutics?
Aquestive Therapeutics maintains updated investor relations information on their corporate website, where investors can gain insights about the firm and its ongoing projects.
